Levosimendan: Implications for clinicians

Journal of Clinical Pharmacology

Volumn 43, Issue 10, 2003, Pages 1071-1081

  McBride, Brian F ^b   White, C Michael ^a  

^a HARTFORD HOSPITAL   (United States)

^b NONE

Author keywords

Acute decompensated heart failure; Calcium sensitization; Levosimendan; Pharmacokinetics

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CALCIUM SENSITIZER; CAPTOPRIL; CARVEDILOL; CATECHOLAMINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENDOTHELIN 1; INOTROPIC AGENT; ISOSORBIDE DINITRATE; LEVOSIMENDAN; MILRINONE; MYOSIN; NEUROHORMONE; NITRATE; NORADRENALIN; PHOSPHODIESTERASE INHIBITOR; POTASSIUM CHANNEL; TROPOMYOSIN; TROPONIN C; TROPONIN I; TROPONIN T; UNINDEXED DRUG; VASODILATOR AGENT; WARFARIN;

ACUTE HEART FAILURE; CALCIUM CELL LEVEL; CHANNEL GATING; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG UTILIZATION; HEART AFTERLOAD; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE NECROSIS; HEART VENTRICLE ARRHYTHMIA; HOSPITAL COST; HUMAN; INOTROPISM; OUTCOMES RESEARCH; PATIENT CARE; PERIPHERAL VASCULAR SYSTEM; PHARMACODYNAMICS; QT INTERVAL; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TORSADE DES POINTES; VASODILATATION;

CALCIUM; CARDIOTONIC AGENTS; CHRONIC DISEASE; CONTROLLED CLINICAL TRIALS; DRUG INTERACTIONS; HEART FAILURE, CONGESTIVE; HUMANS; HYDRAZONES; PYRIDAZINES;

EID: 0141430959     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270003257217     Document Type: Review

References (50)

1. American Heart Association: 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2001.
2. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T: Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc 1990;38:1290-1295.
3. Michalsen A, Konig G, Thimme W: Preventable causative factors leading to hospital admission with decompensated heart failure. Heart 1998;80:437-441.
4. Jiang W, Alander J, Christopher E, Kuchibhata M, Gaulden LH, Cuffe MS, et al: Relationship of depression to increased risk of mortality and rehospitalization in patients congestive heart failure. Arch Intern Med 2001;161:1849-1856.
5. Philbin EF, Dec W, Jenkins PL, DiSalvo TG: Socioeconomic status as an independent risk factor for hospital readmission for heart failure. Am J Cardiol 2001;87:1367-1371.
6. Farquharson CAJ, Strutheres AD: Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-775.
7. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, et al: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999;138(1, Pt. 1):78-86.
8. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991;325:1468-1475.
9. Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized, controlled trial. JAMA 2002;287:1541-1547.
10. Guvton AC, Hall JE: Heart muscle: the heart as a pump, in: Guyton AC, Hall JE (eds.), Textbook of Medical Physiology. 9th ed. Philadelphia: W. B. Saunders, 1996;107-108.
11. Stryer L: Molecular motors, in: Stryer L (ed.), Biochemistry. 4th ed. New York: W. H. Freeman, 1995;402-403.
12. Gwanethmy JK, Slawsky MT, Hajjar RJ, Briggs GM, Morgan JP: Role of intracellular calcium handling in force-interval relationship of human ventricular myocardium. J Clin Invest 1990;85:1599-1613.
13. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alteration in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic heart failure of the failing myocardium. Circ Res 1993;72:463-469.
14. Hasenfuss G, Pieske B, Castell M, Kretschmann B, Maier LS, Just H: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:S45-S51.
15. Hoffman BB, Lefokowitz RJ: Catecholamines, sympathomimetic drugs and adrenergic receptor antagonists, in: Hardman JG, Limbird LE (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed, New York: McGraw-Hill, 1995;199-247.
16. Kelly RA, Smith TW: Pharmacological treatment of heart failure, in: Hardman JG, Limbird LE (eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, 1995;833-834.
17. Barnett DB: The sympathetic nervous system and myocardial adrenoreceptor function and regulation in cardiac failure, in: Barnett DB, Pouleur H, Francis GS (eds.), Congestive Heart Failure: Pathophysiology and Treatment. New York: Marcel-Decker, 1993;34-35.
18. Sorsa T, Heikkinen S, Abbott MB, Abusamhadneh E, Laakso T, Tilgman C, et al: Binding of levosimendan, a calcium sensitizer, to cardiac troponin C. J Biol Chem 2001;276:9337-9343.
19. Kaheinen P, Pollesello P, Levijokiu J, Haikala H: Levosimendan increases diastolic coronary flow in isolated guinea pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 2001;37:367-374.
20. Janssen PM, Datz N, Zeitz O, Hasenfuss G: Levosimendan improves diastolic and systolic function in failing human myocardium. Eur J Pharmacol 2000;404:191-199.
21. Quayle JM, Nelson MT, Standen NB: KATP channels and inwardly rectifying potassium channels in smooth muscle. Physiol Rev 1997;77:109-116.
22. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N: Levosimendan, a novel calcium sensitizer, activates the glibencamide-sensitive potassium channel in rat arterial myocytes. Eur J Pharmacol 1997;333:249-259.
23. Kersten J, Montgomery MW, Pagel PS, Warltier DC: Levosimendan, a new positive inotropic drug, decreases myocardial infract size via activation of KATP channels. Anest Analg 2000;90:5.
24. Ajiro Y, Hagiwara N, Katsube Y, Sperelakis N, Kasanuki H: Levosimendan increases L-type calcium current via phosphodiesterase III inhibition in human cardiac myocytes. Eur J Pharmacol 2002;435:27-33.
25. Bowman P, Haikala H, Paul RJ: Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization. J Pharmacol Exp Ther 1999;288:316-325.
26. Sandell EP, Hayha M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, et al: Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995;26:S57-S62.
27. Figgit DP, Gilles PS, Goa KL: Levosimendan. Drugs 2001;61:613-627.
28. Kortejavari H, Mikkola J, Backman M, Antila S, Marvola M: Development of level A, B, and C in vitro-in vivo correlations for modified release levosimendan capsules [abstract]. Int J Pharmaceutics 2002;241:87-95.
29. Kosekela RV, Hirvonen J, Monkkonen J, Kiesvarra J, Antila S, Lehtonen L, et al: Transdermal delivery of levosimendan. Eur J Pharm Sci 2000;11:343-350.
30. Antila S, Jarvinen A, Honkanen T: Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitizer levosimendan and warfarin. Eur J Clin Pharmacol 2000;56:705-710.
31. Caron, MF, Kalus JS, McBride BF, White CM: Fundamental concepts in pharmacokinetics and pharmacodynamics of antithrombotic agents, in: Becker R, Harrington J (eds.), The Practice of Clinical, Interventional, and Thrombocordiolouy, in press.
32. Antila S, Eha J, Heinpalu M, Lehtonen L, Loogna I, Mesikepp A, et al: Hemodynamic interactions of a new calcium sensitizing agent drug levosimendan and captopril [abstract]. Eur J Clin Pharmacol 1996;49:451-458.
33. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H, et al: Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68:522-531.
34. Sundberg S, Lilleberg J, Nieminen MS, Lehtonen L: Hemodynamic and neurohormonal effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995;75:1061-1066.
35. Bednar MM, Harrigan EP, Anziano RW, et al: The QT interval. Prog Cardio Dis 2001;104(43):1-45.
36. Tran H, White CM, Chow MSS, Kluger J: An evaluation of the impact of gender and age on QT and QTc dispersion among normal individuals. Ann Noninvasive Electrocardiol 2001;6:129-133.
37. White CM, Chow MSS: Cardiac arrhythmias, in: Koda-Kemble MA, Young LY (eds.), Applied Therapeutics: The Clinical Use of Drugs. Philadelphia: Lippincott Williams & Wilkins, 2001;18.1-18.36.
38. Toivonen L, Viitasalo M, Sundberg S, Akkila J, Lehtonen L: Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000;35:664-669.
39. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol 2001;38:2101-2113.
40. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristant F, Rector T, et al: Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation 1993;87(Suppl. VI):VI5-VI16.
41. Hillege H, Armad RJ, deKam PJ, Boomsma F, deZeeuw D, Charlesworth A, et al: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000;102:203-210.
42. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, von Scheidt W: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-1941.
43. Pacher R, Stanek B, Hulsmann M, Strametz JK, Berger R, Schuller M, et al: Prognostic impact of big-endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996;27:633-641.
44. Nicklas JM, Monsur JC, Bleske BE: Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999;83:12(1)-15(1).
45. Neiminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al: Hemodynamic and neurohormonal effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
46. Lilleberg J, Nieminen MS, Akkila J, Heikkila L, Kuitunen A, Lehtonen L, et al: Effects of a new calcium sensitizer, levosimendan, on hemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-668.
47. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC: Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-228.
48. Moiseyyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a placebo-controlled, double blind study (RUSSLAN). Eur Heart J 2002;23:1422-1432.
49. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222-2227.
50. Follath F, Cleland JGF, Papp JGY, Scholz H, Peukurinen K, Harjola VP, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.